Medtronic is rated a 'Buy' due to its attractive valuation and growth potential in its CAS segment, which now accounts for 5-6% of revenue and is growing above $2 billion annually. The company targets 6.75%-7.25% organic growth and $5.90-$6.00 earnings per share, with key factors including calendar effects and the timing of MiniMed separation. Trading at a 25-27% price-to-earnings discount to peers and offering a 3.1% dividend yield, Medtronic is seen as a good accumulation opportunity during market weakness as its turnaround progresses.
Medtronic's board approved a $0.72 per share cash dividend for Q2 of fiscal year 2027, payable on October 16, 2026, to shareholders recorded by September 25. This increase aligns with the company's June 2026 announcement and continues its streak as a...
Medtronic is reaffirmed as a 'Buy' with shares expected to gain over 10% based on strong fundamentals and attractive valuation. The company posted its best organic revenue growth in a decade at 6.6% in Q4, driven by double-digit growth in its Cardiov...
